Absorbed Dose Evaluation in Radioiodine Therapy with Different Approaches
Abstract
:1. Introduction
- (1)
- high-risk group, patients with documented persistent disease or at high risk of persistent or recurrent disease. Postoperative 131I administration reduces the recurrence rate and possibly prolongs survival; it also permits early detection of persistent disease. A high activity of radioiodine is indicated, following the prolonged withdrawal of thyroid hormone treatment, since the use of recombinant human thyroid-stimulating hormone (rhTSH) stimulation has not yet been approved for this indication;
- (2)
- low-risk group, includes all other patients. Benefits are controversial and there are still uncertainties as to whether it should be administered to all patients or only to selected patients. Many clinicians perform ablation in this setting where completeness of thyroidectomy is uncertain; there is no consensus on when surgery has been complete because in this setting benefits are not demonstrated. Whether a low or a high activity should be administered and whether preparation should be achieved by prolonged withdrawal or following rhTSH stimulation are still uncertain and need further studies.
2. Materials and Methods
2.1. Dosimetry in DTC: Red Marrow and Blood Absorbed Dose Calculations
2.1.1. EAMN Method: Blood Dosimetry
2.1.2. AIFM and Traino Method: Red Marrow Dosimetry
2.1.3. BL and WB Measurements and Calculations
3. Results and Discussion
4. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Pacini, F.; Schlumberger, M.; Dralle, H.; Elisei, R.; Smit, J.W.; Wiersinga, W. European Thyroid Cancer Taskforce, European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 2006, 154, 787–803. [Google Scholar] [CrossRef] [PubMed]
- Lassmann, M.; Reiners, C.; Luster, M. Dosimetry and tyhyroid cancer: The individual dosage of radioiodine. Endocr. Relat. Cancer 2010, 17, R161–R172. [Google Scholar] [CrossRef] [PubMed]
- Chiesa, C.; Castellani, M.R.; Vellani, C.; Orunesu, E.; Negri, A.; Azzeroni, R.; Botta, F.; Maccauro, M.; Aliberti, G.; Seregni, E.; et al. Individualized dosimetry in the management of metastatic differentiated thyroid cancer. Q. J. Nucl. Med. Mol. Imaging 2009, 53, 546–561. [Google Scholar] [PubMed]
- Bianchi, L.; Baroli, A.; Lomuscio, G.; Pedrazzini, L.; Pepe, A.; Pozzi, L.; Chiesa, C. Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high 131I activity: The experience of Busto Arsizio Hospital. Q. J. Nucl. Med. Mol. Imaging 2012, 56, 515–521. [Google Scholar] [PubMed]
- Cooper, D.S.; Doherty, G.M.; Haugen, B.R.; Kloos, R.T.; Lee, S.L.; Mandel, S.J.; Mazzaferri, E.L.; McIver, B.; Pacini, F.; Schlumberger, M.; et al. Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2009, 19, 1167–1214. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lassmann, M.; Hänscheid, H.; Chiesa, C.; Hindorf, C.; Flux, G.; Luster, M. EAMN Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry. I: Blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur. J. Nucl. Med. Mol. Imaging 2008, 35, 1405–1412. [Google Scholar] [CrossRef] [PubMed]
- Hindorf, C.; Glatting, G.; Chiesa, C.; Lindén, O.; Flux, G. EAMN Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 1238–1250. [Google Scholar] [CrossRef] [PubMed]
- Molenaar, R.J.; Pleyer, C.; Radivoyevitch, T.; Sidana, S.; Godley, A.; Advani, A.S.; Gerds, A.T.; Carraway, H.E.; Kalaycio, M.; Nazha, A.; et al. Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine. Leukemia 2018, 32, 952–959. [Google Scholar] [CrossRef] [PubMed]
- Molenaar, R.J.; Sidana, S.; Radivoyevitch, T.; Advani, A.S.; Gerds, A.T.; Carraway, H.E.; Angelini, D.; Kalaycio, M.; Nazha, A.; Adelstein, D.J.; et al. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer. J. Clin. Oncol. 2017, 36, 1831–1839. [Google Scholar] [CrossRef] [PubMed]
- Benua, R.S.; Cicale, N.R.; Sonenberg, M.; Rawson, R.W. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am. J. Roentgenol. Radium Ther. Nucl. Med. 1962, 87, 171–182. [Google Scholar] [PubMed]
- Benua, R.S.; Leeper, R.D. A method and rationale for treatment of thyroid carcinoma with the largest, safe dose of 131I. In Frontiers in Thyroidology; Medeiros-Neto, G., Gaitan, E., Eds.; Plenum Medical: New York, NY, USA, 1986; p. 1317. [Google Scholar]
- Maxon, H.R. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q. J. Nucl. Med. 1999, 43, 313–323. [Google Scholar] [PubMed]
- Stabin, M.G.; Siegel, J.A.; Sparks, R.B. Sensitivity of model-based calculations of red marrow dosimetry to changes in patient-specific parameters. Cancer Biother. Radiopharm. 2002, 17, 535–543. [Google Scholar] [CrossRef] [PubMed]
- Chiesa, C.; Indovina, L.; Traino, C.; Sarti, G.; Savi, A.; Amato, E.; De Agostini, A.; Pedroli, G.; Azzeroni, R.; Bianchi, L.; et al. Dosimetria Durante Terapia del Carcinoma Differenziato Della Tiroide Metastatico Protocollo Dosimetrico. 2008. Available online: https://www.aimn.it/pubblicazioni/LG/protocollo_dosimetrico_meta_cdt.pdf (accessed on 7 August 2019).
- Traino, A.C.; Ferrari, M.; Cremonesi, M.; Stabin, M.G. Influence of total-body mass on the scaling of S-factors for patient-specific, blood-based red-marrow dosimetry. Phys. Med. Biol. 2007, 52, 5231–5248. [Google Scholar] [CrossRef] [PubMed]
- Miranti, A.; Giostra, A.; Richetta, E.; Gino, E.; Pellerito, R.E.; Stasi, M. Comparison of mathematical models for red marrow and blood absorbed dose estimation in the radioiodine treatment of advanced differentiated thyroid carcinoma. Phys. Med. Biol. 2015, 60, 1141–1157. [Google Scholar] [CrossRef] [PubMed]
- Gear, J.I.; Cox, M.G.; Gustafsson, J.; Gleisner, K.S.; Murray, I.; Glatting, G.; Konijnenberg, M.; Flux, G.D. EANM practical guidelines on uncertainty analysis for molecular radiotherapy absorbed dose calculations. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 2456–2474. [Google Scholar] [CrossRef] [PubMed]
- Available online: www.labfit.net (accessed on 7 August 2019).
- Verburg, F.A.; Hanscheid, H.; Biko, J.; Hategan, M.C.; Lassmann, M.; Kreissl, M.C.; Reiners, C.; Luster, M. Dosimetry-guided high-activity 131I therapy in patients with advanced differentiated thyroid carcinoma: Initial experience. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 896–903. [Google Scholar] [CrossRef] [PubMed]
- Klubo-Gwiezdzinska, J.; Van Nostrand, D.; Atkins, F.; Burman, K.; Jonklaas, J.; Mete, M.; Wartofsky, L. Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer. Clin. Endocrinol. Metab. 2011, 96, 3217–3225. [Google Scholar] [CrossRef] [PubMed]
- Giostra, A.; Richetta, E.; Pasquino, M.; Miranti, A.; Cutaia, C.; Brusasco, G.; Pellerito, R.E.; Stasi, M. Red marrow and blood dosimetry in 131I treatment of metastatic thyroid carcinoma: Pre-treatment versus in-therapy results. Phys. Med. Biol. 2016, 61, 4316–4326. [Google Scholar] [CrossRef] [PubMed]
- Dorn, R.; Kopp, J.; Vogt, H.; Heidenreich, P.; Carroll, R.G.; Gulec, S.A. Dosimetry-Guided Radioactive Iodine Treatment in Patients with Metastatic Differentiated Thyroid Cancer: Largest Safe Dose Using a Risk-Adapted Approach. J. Nucl. Med. 2003, 44, 451–456. [Google Scholar] [PubMed]
Time (h) | AWB (GBq) | FIAWB |
---|---|---|
2 (full bladder) | 3.70 ± 0.18 | 1.00 ± 0.08 |
2 + 10 minutes (empty bladder) | 3.54 ± 0.35 | 0.96 ± 0.14 |
6 | 2.93 ± 0.29 | 0.79 ± 0.12 |
24 | 1.48 ± 0.15 | 0.40 ± 0.06 |
48 | 0.86 ± 0.09 | 0.23 ± 0.03 |
96 | 0.44 ± 0.04 | 0.12 ± 0.02 |
Time (h) | ||
---|---|---|
2 (full bladder) | 4.85 × 10−2 ± 0.17 × 10−2 | 1.31 × 10−2 ± 0.11 × 10−2 |
6 | 4.59 × 10−2 ± 0.16 × 10−2 | 1.24 × 10−2 ± 0.10 × 10−2 |
24 | 3.34 × 10−2 ± 0.12 × 10−2 | 9.03 × 10−3 ± 0.77 × 10−3 |
48 | 2.29 × 10−2 ± 0.08 × 10−2 | 6.20 × 10−3 ± 0.53 × 10−3 |
96 | 4.37 × 10−3 ± 0.15 × 10−3 | 1.18 × 10−3 ± 0.10 × 10−3 |
EAMN | AIFM | Traino | ||
---|---|---|---|---|
18.48 ± 3.31 | 3.43 × 10−4 ± 0.64 × 10−4 | 3.69 × 10−2 ± 1.25 × 10−2 | 2.20 × 10−2 ± 0.77 × 10−2 | 2.74 × 10−2 ± 0.96 × 10−2 |
EAMN | AIFM | Traino | |
---|---|---|---|
MTA (GBq) | 14.65 ± 5.13 | 24.57 ± 8.60 | 20.02 ± 7.00 |
AIFM-EAMN | Traino-EAMN | AIFM-Traino | |
---|---|---|---|
% diff. | 40 | 26 | 20 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Mazzaglia, S.; Stella, G.; Barone Tonghi, L.; Tuvé, C.N.; Politi, G.; Pellegriti, G.; Gueli, A.M. Absorbed Dose Evaluation in Radioiodine Therapy with Different Approaches. Instruments 2019, 3, 39. https://doi.org/10.3390/instruments3030039
Mazzaglia S, Stella G, Barone Tonghi L, Tuvé CN, Politi G, Pellegriti G, Gueli AM. Absorbed Dose Evaluation in Radioiodine Therapy with Different Approaches. Instruments. 2019; 3(3):39. https://doi.org/10.3390/instruments3030039
Chicago/Turabian StyleMazzaglia, Stefania, Giuseppe Stella, Letizia Barone Tonghi, Cristina N. Tuvé, Giuseppe Politi, Gabriella Pellegriti, and Anna M. Gueli. 2019. "Absorbed Dose Evaluation in Radioiodine Therapy with Different Approaches" Instruments 3, no. 3: 39. https://doi.org/10.3390/instruments3030039